Back to Search Start Over

Oxidative stress biomarkers in Fabry disease: is there a room for them?

Authors :
Alessandro Salviati
Irene Simonetta
Costanza Simoncini
Michelangelo Mancuso
V. Cianci
Daniela Concolino
V. Vicenzi
Ginevra De Marchi
Antonino Tuttolomondo
V. Montano
Lucia Chico
Simona Sestito
Marialuisa Zedde
Domenico Girelli
Gabriele Siciliano
Francesco Gruosso
Antonio Pinto
S. Torri
Simoncini C.
Torri S.
Montano V.
Chico L.
Gruosso F.
Tuttolomondo A.
Pinto A.
Simonetta I.
Cianci V.
Salviati A.
Vicenzi V.
Marchi G.
Girelli D.
Concolino D.
Sestito S.
Zedde M.
Siciliano G.
Mancuso M.
Source :
Journal of Neurology
Publication Year :
2020
Publisher :
Springer Science and Business Media LLC, 2020.

Abstract

Background Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by deficient activity of the alpha-galactosidase A enzyme leading to progressive and multisystemic accumulation of globotriaosylceramide. Recent data point toward oxidative stress signalling which could play an important role in both pathophysiology and disease progression. Methods We have examined oxidative stress biomarkers [Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), thiolic groups] in blood samples from 60 patients and 77 healthy controls. Results AOPP levels were higher in patients than in controls (p p Conclusions Oxidative stress occurs in FD in both treated and naïve patients, highlighting the need of further research in oxidative stress-targeted therapies. Furthermore, we found that oxidative stress biomarkers may represent early markers of disease in treatment-naïve patients with a potential role in helping interpretation of FD-related mutations and time to treatment decision.

Details

ISSN :
14321459 and 03405354
Volume :
267
Database :
OpenAIRE
Journal :
Journal of Neurology
Accession number :
edsair.doi.dedup.....5ed1004f69eddd8d64bbe6ac519903c2